MKRN1 and metabolic syndrome: The second jump (p = 0.00019) was for the 11th most T2D relevant article in week 41 which concludes with ‘implicating MKRN1 as a possible therapeutic target for metabolic syndromes, such as obesity, type II diabetes, and fat liver diseases’ [61].